Yakult Honsha, Taiho to Call Off Plan to Co-Promote Oxaliplatin

Yakult Honsha (TSE: 2267) announced on April 5 that the company has decided to cancel its plan to co-promote oxaliplatin with Taiho Pharmaceutical. Oxaliplatin, which is currently pending for import approval, is an agent used in the treatment of colorectal cancer. Since the use of oxaliplatin is confined to therapies combined with continuous intravenous administrations of fluorouracil and levofolinate, the two companies have concluded that co-promotion would be less profitable than expected.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=9777)